BioLineRx Enters Co-Development Agreement with GenFleet to Further Develop Motixafortide in Pancreatic Ductal Adenocarcinoma (PDAC), Advised by MSQ Ventures
M.S.Q. Ventures (“MSQ”) is pleased to announce that its client, BioLineRx Ltd. (“BioLineRx”) (NASDAQ/TASE: BLRX), has successfully entered into a co-development agreement with GenFleet Therapeutics, Inc., an immuno-oncology focused biopharmaceutical company based in Shanghai, China, for the development of Motixafortide in pancreatic ductal adenocarcinoma (“PDAC”). Under the terms of the agreement, GenFleet…
